Next Article in Journal
Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
Previous Article in Journal
Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents?
 
 
Article

Article Versions Notes

Cancers 2022, 14(10), 2352; https://doi.org/10.3390/cancers14102352
Action Date Notes Link
article xml file uploaded 10 May 2022 11:08 CEST Original file -
article xml uploaded. 10 May 2022 11:08 CEST Update https://www.mdpi.com/2072-6694/14/10/2352/xml
article pdf uploaded. 10 May 2022 11:08 CEST Version of Record https://www.mdpi.com/2072-6694/14/10/2352/pdf
article supplementary file uploaded. 10 May 2022 11:08 CEST - https://www.mdpi.com/2072-6694/14/10/2352#supplementary
article html file updated 10 May 2022 11:10 CEST Original file -
article html file updated 2 August 2022 23:04 CEST Update https://www.mdpi.com/2072-6694/14/10/2352/html
Back to TopTop